- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01678079
Encapsulated Calcium Absorption in Pregnancy (ENCAP)
November 17, 2014 updated by: Daniel Roth, The Hospital for Sick Children
Bioavailability and Acceptability of Enteric-Coated Microencapsulated Calcium During Pregnancy: A Randomized Crossover Trial in Bangladesh (Encapsulated Calcium Absorption in Pregnancy)
This study will enroll at least 60 pregnant women in a randomized cross-over study in Dhaka, Bangladesh.
Each participant will be randomized to one of 3 calcium doses: 500 mg, 1000 mg, 1500 mg elemental Ca per day.
Each participant will undergo two calcium absorption tests, one with a micronutrient supplement powder containing non-encapsulated (non-coated) calcium and the other with a micronutrient supplement powder containing encapsulated calcium at the same dose.
The absorption tests will be separated by a 2-week washout period.
Fractional calcium absorption will be measured using the dual stable isotope method.
For each test, the formulation will be administered orally for 9 days; on the 10th day, a 44Ca- labeled stable isotope will be given orally and a 42Ca-labeled stable isotope dose will be given intravenously.
Urine will be collected for 48 hours to measure calcium absorption.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Dhaka, Bangladesh
- International Center for Diarrheal Disease Research
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
Maryland
-
Baltimore, Maryland, United States, 21213
- The Johns Hopkins Bloomberg School of Public Health
-
-
Texas
-
Houston, Texas, United States
- Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 30 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women aged 18 to 30 years
- Current residence in Dhaka at a fixed address
- Plan to remain in Dhaka for at least 2 months from date of enrolment
- Gestational age of 27 completed weeks ± 1 week, estimated based on the recalled first day of the last menstrual period (LMP)
Exclusion Criteria:
- Complicated medical or obstetric history, based on self-report or clinical assessment by physician (e.g., cardiovascular disease, uterine hemorrhage, placenta previa, threatened abortion, hypertension, preeclampsia, multiple gestation, diabetes, renal disease)
Higher risk pregnancy based on one or more of the following clinical findings at time of recruitment:
- Severe anemia (hemoglobin <70 g/L assessed by Hemocue)
- Proteinuria (≥ 100 mg/dl based on urine dipstick)
- Glycosuria (≥ 100 mg/dl based on urine dipstick)
- Hypertension (systolic blood pressure, ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg)
- Reported use of dietary supplements that contain >500 mg of calcium per day and/or >400 IU (10 mcg) of vitamin D per day
- Reported use (chewing) of betel leaf, areca nut and lime (together referred to locally as paan) during pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Micronutrient Powder, Enteric-coated Calcium (500 mg/day)
Encapsulated Calcium
|
The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
|
Experimental: Micronutrient Powder, Enteric-coated Calcium (1000 mg/day)
Encapsulated Calcium
|
The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
|
Experimental: Micronutrient Powder, Enteric-coated Calcium (1500 mg/day)
Encapsulated Calcium
|
The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
|
Active Comparator: Micronutrient Powder, Uncoated Calcium (500 mg/day)
Non-capsulated Calcium
|
The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
|
Active Comparator: Micronutrient Powder, Uncoated Calcium (1000 mg/day)
Non-capsulated Calcium
|
The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
|
Active Comparator: Micronutrient Powder, Uncoated Calcium (1500 mg/day)
Non-capsulated Calcium
|
The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional Calcium Absorption
Time Frame: Fractional calcium absorption during day 10-11
|
The primary analysis will be a comparison of mean fractional absorption of the two calcium formulations (enteric-coated vs. non-coated).
The secondary analysis will be a comparison of mean fractional absorption across different calcium doses (500, 1000, 1500 mg per day).
|
Fractional calcium absorption during day 10-11
|
Fractional Calcium Absorption
Time Frame: Fractional calcium absorption during day 35-36
|
The primary analysis will be a comparison of mean fractional absorption of the two calcium formulations (enteric-coated vs. non-coated).
The secondary analysis will be a comparison of mean fractional absorption across different calcium doses (500, 1000, 1500 mg per day).
|
Fractional calcium absorption during day 35-36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Palatability and Acceptability
Time Frame: Baseline, +10/11 days, +35/36 days
|
The palatability and acceptability of the microencapsulated and non-encapsulated calcium formulations will be surveyed to assess the following parameters using semi-quantitative measures (i.e.
Organoleptic properties, such as taste, odour, texture and colour, and adherence to prescribed micronutrient regimen, and reasons for non-adherence)
|
Baseline, +10/11 days, +35/36 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Roth, MD, The Hospital for Sick Children
- Principal Investigator: Stanley Zlotkin, MD, The Hospital for Sick Children
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Actual)
June 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
August 30, 2012
First Submitted That Met QC Criteria
August 31, 2012
First Posted (Estimate)
September 3, 2012
Study Record Updates
Last Update Posted (Estimate)
November 18, 2014
Last Update Submitted That Met QC Criteria
November 17, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1000033463
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Hopital Antoine BeclereUnknown
Clinical Trials on Encapsulated Calcium
-
AZ-VUBUniversitaire Ziekenhuizen KU Leuven; Universitair Ziekenhuis BrusselUnknown
-
Robert BrummerActive, not recruiting
-
Jena University HospitalGerman Federal Ministry of Education and ResearchNot yet recruitingInflammatory Bowel Diseases | Ulcerative Colitis
-
Arne AstrupBiocare Copenhagen A/SCompletedAppetite; Lack or Loss, Nonorganic OriginDenmark
-
Microbiome Health Research InstituteUniversity of Wisconsin, Madison; Indiana UniversityCompletedAntibiotic Resistant StrainUnited States
-
University of GalwayHealth Research Board, IrelandNot yet recruitingOrthostatic Hypotension
-
Nordin HanssenRecruiting
-
Instituto Nacional de RehabilitacionNational Council of Science and Technology, MexicoCompletedTear; Knee, Cartilage, ArticularMexico
-
Swiss Federal Institute of TechnologyCompleted
-
H. Lundbeck A/SCompleted